What is Northland Securities’ Forecast for HRTX Q1 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for Heron Therapeutics in a research report issued on Thursday, February 26th. Northland Securities analyst C. Byrnes expects that the biotechnology company will earn ($0.01) per share for the quarter. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Securities also issued estimates for Heron Therapeutics’ Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.00 EPS.

Several other research firms have also recently commented on HRTX. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Zacks Research cut shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Heron Therapeutics in a report on Friday, January 9th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Heron Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Stock Down 0.8%

Heron Therapeutics stock opened at $1.19 on Monday. Heron Therapeutics has a twelve month low of $1.00 and a twelve month high of $2.68. The company has a debt-to-equity ratio of 10.59, a quick ratio of 1.51 and a current ratio of 2.48. The firm has a market cap of $224.36 million, a PE ratio of -9.15 and a beta of 1.26. The firm’s 50 day moving average price is $1.30 and its two-hundred day moving average price is $1.27.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $40.59 million for the quarter, compared to analysts’ expectations of $39.53 million.

Institutional Trading of Heron Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP grew its position in Heron Therapeutics by 3.3% during the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock worth $39,061,000 after acquiring an additional 946,100 shares during the last quarter. Clearline Capital LP boosted its stake in Heron Therapeutics by 26.0% in the fourth quarter. Clearline Capital LP now owns 12,235,239 shares of the biotechnology company’s stock valued at $15,906,000 after acquiring an additional 2,522,712 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in Heron Therapeutics by 9.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock worth $14,541,000 after acquiring an additional 946,100 shares during the period. Velan Capital Investment Management LP raised its position in shares of Heron Therapeutics by 25.3% during the 3rd quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock valued at $11,029,000 after acquiring an additional 1,766,546 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Heron Therapeutics by 2,785.2% in the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock valued at $9,321,000 after purchasing an additional 6,921,405 shares during the last quarter. 80.01% of the stock is owned by institutional investors.

Key Heron Therapeutics News

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results and company guidance: Heron reported Q4 revenue of $40.59M and EPS of ($0.02), both modest beats vs. Street estimates, and reported full‑year 2025 net revenue of $154.9M (65% YoY growth driven by ZYNRELEF and APONVIE). Management issued FY2026 net revenue guidance of $173–$183M and adjusted EBITDA guidance of $10–$20M — a clear near‑term commercial growth signal. Heron Press Release
• Positive Sentiment: HC Wainwright reiterates Buy and $6 target: Analyst B. Folkes continues to rate HRTX a Buy and models a multi‑year recovery to profitability (FY2027+), including an eventual FY2030 EPS of $0.55 — signaling meaningful upside from current levels if execution and product growth continue. (HC Wainwright research note)
• Neutral Sentiment: HC Wainwright near‑term modeling: The firm provided detailed Q1–Q4 2026 EPS estimates (Q1 -$0.03, Q2 -$0.02, Q3 -$0.01, Q4 $0.00) and a FY2026 consensus around -$0.13 — useful visibility but not an immediate catalyst. (HC Wainwright research note)
• Neutral Sentiment: Coverage and takeaways from the quarter are circulating: earnings call highlights and analyst write‑ups summarize the beat, commercial momentum, and guidance. These pieces help investors parse the quarter but largely echo the company release. Earnings Call Highlights Zacks Analysis WTOP Snapshot
• Negative Sentiment: Modest medium‑term EPS downgrades from HC Wainwright: The analyst trimmed FY2027, FY2028 and FY2029 EPS forecasts slightly (FY2027 to $0.14 from $0.15; FY2028 to $0.39 from $0.43; FY2029 to $0.44 from $0.48). Those cuts reduce some of the upside implied by prior estimates and may have tempered enthusiasm after recent share gains. (HC Wainwright research note)

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.